Alabama is currently home to 1232 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Birmingham, Mobile, Huntsville and Anniston. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Testing RG1-VLP Vaccine to Prevent HPV-related Cancers
NCT05985681
Recruiting
This phase I trial tests the safety, side effects, and best dose of RG1-virus-like particle (VLP) in preventing human papillomavirus (HPV)-related cancers in women. RG1-VLP is a vaccine that aims to protect against rare HPV types not targeted by currently approved HPV vaccines. HPV is a common sexually-transmitted infection that can cause certain genital and oral cancers. RG1-VLP contains a protein of HPV type 16 (HPV16) with a slightly different structure than the licensed Gardasil-9 vaccine. G... Read More
Gender:
FEMALE
Ages:
Between 18 years and 45 years
Trial Updated:
03/06/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama
Conditions: Human Papillomavirus-Related Carcinoma
Register for Updates
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
NCT05966480
Recruiting
The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
03/06/2025
Locations: Investigator Site #1046, Anniston, Alabama
Conditions: SLE
Register for Updates
Developing an Opioid Taper Intervention Before Total Joint Arthroplasty
NCT05788016
Recruiting
The goal of this clinical trial is to develop an pharmacist-led preoperative opioid taper intervention for patients undergoing total knee or hip replacement who are on chronic opioids before their surgery. The main questions it aims to answer are: * Is the intervention feasible and acceptable to patients? * Does the intervention result in a decrease in opioid dose during the preoperative period? Participants will meet with a clinical pharmacist, who will provide some basic education on pain an... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/06/2025
Locations: UAB Hospital-Highlands, Birmingham, Alabama
Conditions: Arthritis Knee, Arthritis Hip, Chronic Pain
Register for Updates
Usage of Spirometry in Managing IgG Therapy in CVID with Airway Disease
NCT05193552
Recruiting
Although there is evidence in the literature that gammaglobulin replacement therapy can lead to a reduction in the prevalence of pulmonary infection and improved lung function, there is no published study to guide immunologists regarding the use of spirometry in titrating IG therapy to assist in the management of immunodeficiency patients with regards to gammaglobulin replacement therapy. The investigators propose to study the use of spirometry to identify patients that could potentially benefi... Read More
Gender:
ALL
Ages:
21 years and above
Trial Updated:
03/06/2025
Locations: Community Health 20, Birmingham, Alabama
Conditions: Common Variable Immunodeficiency
Register for Updates
RAD 1802: Pilot Trial of Five Fraction Stereotactic Body Radiotherapy for Early Stage Breast Cancer Patients Eligible for Post-Operative Accelerated Partial Breast Irradiation (APBI)
NCT03643861
Recruiting
This study offers 5 fractions of radiation treatment through partial breast irradiation in patients with early stage breast cancer after having a lumpectomy.
Gender:
ALL
Ages:
Between 18 years and 99 years
Trial Updated:
03/06/2025
Locations: University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center (HSROC), Birmingham, Alabama
Conditions: Breast Cancer
Register for Updates
Amnio-Maxx in Patients with Diabetic Foot Ulcers Unresponsive to Standard of Care Treatment Alone
NCT06572839
Recruiting
This randomized controlled study evaluates the adjuvant use of Amnio-Maxx in patients with diabetic foot ulcers
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: North Alabama Research Center, LLC, Athens, Alabama
Conditions: Diabetic Foot Ulcer
Register for Updates
CROSSOVER STUDY OF ON-DEMAND PREP FORMULATIONS COMPARING RECTAL AND ORAL TENOFOVIR
NCT06560684
Recruiting
This is a Phase 2, multi-site, two-period, open label randomized crossover (Period 1 and 2) study. Participants are randomized 1:1 to one of two 8-week on-demand product sequences - TFV douche then oral F/TDF or oral F/TDF then TFV douche - with a 2 to 4-week washout period in between. Domains of safety, acceptability, adherence, and PK/PD (sub-study only) are assessed for each product.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: Alabama CRS (Site ID# 31788), Birmingham, Alabama
Conditions: Tenofovir
Register for Updates
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
NCT06472089
Recruiting
The goal of this study is to evaluate whether a psychological intervention (BMT-CARE) is effective at improving the quality of life in caregivers and patients treated with hematopoietic cell transplant compared to usual care, and to identify critical facilitators and barriers for BMT-CARE implementation and adoption.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/05/2025
Locations: University of Alabama at Brimingham, Birmingham, Alabama
Conditions: Bone Marrow Transplant Complications, Hematologic Malignancy
Register for Updates
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
NCT06141473
Recruiting
The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral dose of teriflunomide in male and female participants with relapsing forms of multiple sclerosis (aged 18 to 55 years at the time of enrollment). People diagnosed with relapsing forms of multiple sclerosis are eligible for enrollment as long as they meet all the inclusion criteria and none of the exclusion criteria. Study details include: * This eve... Read More
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
03/05/2025
Locations: Alabama Neurology Associates- Site Number : 8400115, Birmingham, Alabama
Conditions: Multiple Sclerosis
Register for Updates
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972
Recruiting
The purpose of this study is to evaluate long-term safety and tolerability of ianalumab in participants with systemic lupus erythematosus who have previously completed the treatment period in one of the two SIRIUS-SLE core studies (CVAY736F12301 or CVAY736F12302).
Gender:
ALL
Ages:
Between 12 years and 100 years
Trial Updated:
03/05/2025
Locations: Pinnacle Research Group Llc, Anniston, Alabama
Conditions: Systemic Lupus Erythematosus
Register for Updates
A Study of XTMAB-16 in Patients With Pulmonary Sarcoidosis
NCT05890729
Recruiting
A phase 1b/2 study of XTMAB-16 in patients with pulmonary sarcoidosis
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/05/2025
Locations: Xentria Investigative Site, Birmingham, Alabama
Conditions: Pulmonary Sarcoidosis
Register for Updates
Sex, Hormones and Identity Affect Nociceptive Expression
NCT05787470
Recruiting
The Investigators have recently published on differences in pain sensitivity measures between cis and trans individuals in the local area. The investigators observed the anticipated differences in pain sensitivity between CM and CW (CW \> CM), but found that the TW were phenotypically similar to CW in all measures. However, the investigators did not assess hormone level, nor did the investigators recruit TM participants. Here, with the assistance of two local community group stakeholders the inv... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
03/05/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama
Conditions: Pain, Gender Identity
Register for Updates